MaxCyte director granted RSUs and stock options

MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options.

Rhea-AI Filing Summary

MAXCYTE, INC. director Brooke William W received equity awards consisting of common stock and stock options. He was granted 30,421 shares of Common Stock in the form of restricted stock units, each representing a right to one share. These RSUs vest on June 17, 2027, if he continues serving as a non-employee director under the company’s Equity Grant Policy. He was also granted stock options for 49,579 shares of Common Stock at an exercise price of $1.13 per share, expiring on June 16, 2036. Following these awards, he directly holds 181,300 shares of Common Stock.

Insider Trade Summary

Grant/Award: 80,000 shares

Grant/Award 2 txns

Insider Brooke William W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	49,579	$0.00	$0.00
Grant/Award	Common Stock	30,421	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 49,579 contracts (Direct); Common Stock — 181,300 shares (Direct)

Footnotes (2)

1. F1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
2. F2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

Key Figures

RSU grant: 30,421 units Option grant size: 49,579 options Option exercise price: $1.13 per share +2 more

5 metrics

RSU grant 30,421 units Annual equity grant for non-employee director

Option grant size 49,579 options Stock Option (right to buy) underlying common shares

Option exercise price $1.13 per share Conversion or exercise price for stock options

Common shares held after grant 181,300 shares Total shares following non-derivative transaction

Option expiration June 16, 2036 Expiration date of stock options

Key Terms

restricted stock units ("RSUs"), Equity Grant Policy, Stock Option (right to buy)

3 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share"

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Equity Grant Policy financial

"This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors."

Stock Option (right to buy) financial

"Stock Option (right to buy) ... underlying security title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did director Brooke William W receive in this MAXCYTE (MXCT) Form 4 filing?

Director Brooke William W received equity awards in MAXCYTE, INC., including restricted stock units and stock options. The grants are compensation for his service as a non-employee director under the company’s Equity Grant Policy and increase his overall direct equity position.

How many restricted stock units did Brooke William W receive from MAXCYTE (MXCT)?

He received 30,421 restricted stock units, each representing a contingent right to one share of MAXCYTE common stock. These RSUs do not convert immediately; they turn into shares only upon vesting, assuming he continues serving as a non-employee director through the vesting date.

When do the MAXCYTE (MXCT) restricted stock units granted to Brooke William W vest?

The RSUs granted to Brooke William W vest on June 17, 2027, subject to his continuous service. This means he must remain a non-employee director through that date to receive the underlying shares of common stock covered by this annual equity grant.

What stock options were granted to Brooke William W by MAXCYTE (MXCT)?

He was granted stock options covering 49,579 shares of MAXCYTE common stock at an exercise price of $1.13 per share. These options give him the right, but not the obligation, to buy those shares at that price before their stated expiration date.

When do Brooke William W’s MAXCYTE (MXCT) stock options expire?

The stock options reported in this filing expire on June 16, 2036, if not exercised earlier. After that expiration date, he would no longer be able to purchase MAXCYTE common shares at the $1.13 exercise price associated with this option grant.

How many MAXCYTE (MXCT) shares does Brooke William W hold after these grants?

After the reported equity awards, Brooke William W directly holds 181,300 shares of MAXCYTE common stock. This figure reflects his direct ownership position following the new grant of 30,421 restricted stock units reported in the non-derivative transaction section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brooke William W

(Last) (First) (Middle)

C/O MAXCYTE, INC.

9713 KEY WEST AVENUE, SUITE 400

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MAXCYTE, INC. [ MXCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/17/2026		A		30,421(1)(2)	A	$0	181,300	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.13	06/17/2026		A		49,579		(2)	06/16/2036	Common Stock	49,579	$0	49,579	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

2. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 17, 2027, subject to the reporting person's continuous service as of such vesting date.

	/s/ Maher Masoud, Attorney-in-Fact	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)